Featured Research

from universities, journals, and other organizations

Researchers Identify An Enzyme That Regulates The Action Of Chronic Cocaine

Date:
March 15, 2001
Source:
Rockefeller University
Summary:
Scientists have found that an enzyme called Cdk5 regulates the action of chronic cocaine in the brain. In a paper published in the March Nature, members of Paul Greengard's Laboratory of Molecular and Cellular Neuroscience and colleagues at other institutions identify Cdk5's role in the long-term changes associated with cocaine addiction.

Scientists have found that an enzyme called Cdk5 regulates the action of chronic cocaine in the brain. In a paper published in the March Nature, members of Paul Greengard's Laboratory of Molecular and Cellular Neuroscience and colleagues at other institutions identify Cdk5's role in the long-term changes associated with cocaine addiction. By combining behavioral and biochemical studies, they found that Cdk5 (which stands for cyclin-dependent kinase 5) is a key player in a series of biochemical events that occur in certain brain cells with exposure to chronic cocaine.

Cocaine addiction develops through repeated exposure to the drug. In response, the brain attempts to maintain equilibrium by countering the effects of repeated drug administration. Chronic exposure to cocaine can set a series of chemical reactions in motion that lead to changes in the expression pattern of certain genes that then "feed back" to block the effects of cocaine. This succession of events appears to underlie the adaptive changes occurring in the addictive brain.

"By finding new inhibitors to this pathway, we might find compounds that have a palliative effect, removing the craving for cocaine similar to the way methadone removes the craving for heroin," says Research Associate James Bibb, senior author on the paper.

Cdk5 regulates certain effects of chronic cocaine by controlling the signaling of a neurotransmitter called dopamine. Dopamine is involved in fine motor control, reward and reproductive behavior, but abnormalities in dopamine signaling are associated with several neurological and psychiatric disorders, including substance abuse. When dopamine is released in the brain, it binds to a receptor and starts a cascade of biochemical events. Cdk5 is important to this process because it activates a key molecule involved in dopamine signaling called DARPP-32.

"We had shown earlier that DARPP-32 is a major player in the mechanisms by which dopamine produces its effects in the brain," says Greengard, Vincent Astor Professor and director of the Zachary and Elizabeth Fisher Center for Research on Alzheimer's Disease at Rockefeller. In the current study, the laboratory was looking for causes and co-factors of addiction.

Cdk5 became an appealing target for this research when co-author Eric Nestler, now at Univeristy of Texas Southwestern Medical Center in Dallas, first found that expression of the Cdk5 gene goes up in mice genetically altered to serve as a model for drug abuse. In subsequent behavioral studies conducted by Jane Taylor in the Psychiatry Department at Yale University, the effects of a drug, roscovitine, which inhibits Cdk5, were assessed in rats that were also exposed repeatedly to cocaine. The results indicated that cocaine-induced increases in Cdk5 levels serve to dampen responses to subsequent drug exposure. The Nature paper also shows that repeated exposure to cocaine enhanced the biochemical pathway between Cdk5 and DARPP-32 resulting in reduced sensitivity of the dopamine receptors involved in mediating the behavioral effects of cocaine.

Other coauthors on the paper include Per Svenningsson, Akinori Nishi, Gretchen Snyder, Zachary Sagawa, and Angus Nairn from Rockefeller University, Jingshan Chen from the Department of Psychiatry at Yale University, and Charles Ouimet from the Program in Neuroscience at Florida State University.

Funding for the research was provided by National Institute for Drug Abuse and the National Institute for Mental Health. Greengard is Vincent Astor Professor and head of the Laboratory of Molecular and Cellular Neuroscience at The Rockefeller University. He shared the 2000 Nobel Prize in Physiology or Medicine for his discovery of how dopamine and a number of other transmitters in the brain exert their action in the nervous system.

John D. Rockefeller founded Rockefeller University in 1901 as The Rockefeller Institute for Medical Research. Rockefeller scientists have made significant achievements, including the discovery that DNA is the carrier of genetic information. The University has ties to 21 Nobel laureates, six of whom are on campus. At present, 32 faculty are elected members of the U.S. National Academy of Sciences, including the president, Arnold J. Levine, Ph.D. Celebrating its centennial anniversary in 2001, Rockefeller — the nation’s first biomedical research center—continues to lead the field in both scientific inquiry and the development of tomorrow’s scientists.


Story Source:

The above story is based on materials provided by Rockefeller University. Note: Materials may be edited for content and length.


Cite This Page:

Rockefeller University. "Researchers Identify An Enzyme That Regulates The Action Of Chronic Cocaine." ScienceDaily. ScienceDaily, 15 March 2001. <www.sciencedaily.com/releases/2001/03/010315075710.htm>.
Rockefeller University. (2001, March 15). Researchers Identify An Enzyme That Regulates The Action Of Chronic Cocaine. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2001/03/010315075710.htm
Rockefeller University. "Researchers Identify An Enzyme That Regulates The Action Of Chronic Cocaine." ScienceDaily. www.sciencedaily.com/releases/2001/03/010315075710.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins